| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2023―Jun―21 |
The priority for prevention and control of infectious diseases: Reform of the Centers for Disease Prevention and Control - Occasioned by "the WHO chief declares end to COVID-19 as a global health emergency" |
Mingyu Luo, Fuzhe Gong, Jinna Wang, Zhenyu Gong |
| 2 |
[GO] |
2023―Mrz―13 |
Sequelae of long COVID, known and unknown: A review of updated information |
Tetsuya Asakawa, Qingxian Cai, Jiayin Shen, Ying Zhang, Yongshuang Li, Peifen Chen, Wen Luo, Jiangguo Zhang, Jinfeng Zhou, Hui Zeng, Ruihui Weng, Feng Hu, Huiquan Feng, Jun Chen, Jie Huang, Xiaoyin Zhang, Yu Zhao, Liekui Fang, Rongqing Yang, Jia Huang, Fuxiang Wang, Yingxia Liu, Hongzhou Lu |
| 3 |
[GO] |
2023―Feb―10 |
Simulation of SARS-CoV-2 epidemic trends in Tokyo considering vaccinations, virus mutations, government policies and PCR tests |
Jianing Chu, Hikaru Morikawa, Yu Chen |
| 4 |
[GO] |
2023―Jan―21 |
Different clinical guidelines, common goal: To reduce COVID-19 mortality |
Liqin Sun, Jiaye Liu, Fang Zhao, Jun Chen, Hongzhou Lu |
| 5 |
[GO] |
2023―Jan―16 |
Pre-enriched saline gargle samples for detection of SARS-CoV-2 |
Peng Xu, Jing Chen, Chengchen Qian, Wenqiang Yu |
| 6 |
[GO] |
2023―Jan―15 |
For COVID-19, what are the priorities of normalized prevention and control strategies? |
Mingyu Luo, Fuzhe Gong, Jimin Sun, Zhenyu Gong |
| 7 |
[GO] |
2023―Jan―01 |
Herbal medicines exhibit a high affinity for ACE2 in treating COVID-19 |
Bo Zhang, Fanghua Qi |
| 8 |
[GO] |
2022―Dez―25 |
Trends in managing COVID-19 from an emerging infectious disease to a common respiratory infectious disease: What are the subsequent impacts on and new challenges for healthcare systems? |
Kenji Karako, Peipei Song, Yu Chen, Takashi Karako |
| 9 |
[GO] |
2022―Dez―25 |
Is targeting angiotensin-converting enzyme 2 (ACE2) a prophylactic strategy against COVID-19? |
Jing Li, Yufen Yan, Fangzhou Dou, Jianjun Gao |
| 10 |
[GO] |
2022―Dez―08 |
Can nasal irrigation with chlorine dioxide be considered as a potential alternative therapy for respiratory infectious diseases? The example of COVID-19 |
Jing Cao, Yirong Shi, Min Wen, Yuanyuan Peng, Qiqi Miao, Xiaoning Liu, Mingbin Zheng, Tetsuya Asakawa, Hongzhou Lu |
| 11 |
[GO] |
2022―Dez―08 |
Focusing on development of novel sampling approaches and alternative therapies for COVID-19: Are they still useful in an era after the pandemic? |
Tetsuya Asakawa |
| 12 |
[GO] |
2022―Dez―08 |
Verification of the efficiency of saline gargle sampling for detection of the Omicron variant of SARS-CoV-2, a pilot study |
Kun Qiao, Xiaoting Tao, Houming Liu, Mingbin Zheng, Tetsuya Asakawa, Hongzhou Lu |
| 13 |
[GO] |
2022―Sep―11 |
An average of nearly 200,000 new infections per day over a six-week period: What is the impact of such a severe COVID-19 pandemic on the healthcare system in Japan? |
Kenji Karako, Peipei Song, Yu Chen, Takashi Karako |
| 14 |
[GO] |
2022―Jul―29 |
Heparin therapy in COVID-19: Call for randomized controlled trials (RCTs) |
Tingting Fang, Xianyang Pan, Ju Huang, Jun Chen, Shuli Song, Qilin Zhan |
| 15 |
[GO] |
2022―Jul―16 |
The role of influenza in the era of COVID-19: Can we forget it? |
Ting Li, Tetsuya Asakawa, Hui Liu, Cordia Chu, Hongzhou Lu |
| 16 |
[GO] |
2022―Jun―21 |
How should designated COVID-19 hospitals in megacities implement a precise management strategy in response to Omicron? |
Jing Cao, Min Wen, Yirong Shi, Ting Huang, Yunlan Yi, Youfeng Su, Xiaohui Liu, Yanling Chao, Hongzhou Lu |
| 17 |
[GO] |
2022―Jun―21 |
Treating patients infected with the SARS-CoV-2 Omicron variant with a traditional Chinese medicine, Shufeng Jiedu capsule |
Jing Zhang, Lili Liu, Guoliang Zhang, Mingqiang Li, Bitao Ma, Wenming Yang |
| 18 |
[GO] |
2022―Jun―16 |
Needs of cancer patients during the SARS-CoV-2 Omicron lockdown: A population-based survey in Shanghai, China |
Minxing Chen, Ruijia Li, Gang Ding, Chunlin Jin |
| 19 |
[GO] |
2022―Mrz―16 |
An innovative two-wing model for balancing the demands of inpatients with COVID-19 and general medical service in a designated hospital for COVID-19 in Shenzhen, China |
Xiaoning Liu, Jing Cao, Yiling Ji, Ting Li, Zheng Zhu, Ting Huang, Hongzhou Lu |
| 20 |
[GO] |
2021―Dez―27 |
The strategy behind Japan's response to COVID-19 from 2020-2021 and future challenges posed by the uncertainty of the Omicron variant in 2022 |
Peipei Song, Takashi Karako |
| 21 |
[GO] |
2021―Dez―17 |
From SARS to the Omicron variant of COVID-19: China's policy adjustments and changes to prevent and control infectious diseases |
Mingyu Luo, Qinmei Liu, Jinna Wang, Zhenyu Gong |
| 22 |
[GO] |
2021―Aug―29 |
Considerations and guidance to control the rebound in COVID-19 cases |
Qian Li, Xiangming Zhan, Jun Wang, Hongzhou Lu |
| 23 |
[GO] |
2021―Aug―24 |
Update: Drug treatment options for coronavirus disease 2019 (COVID-19) |
Yueming Shao, Jun Chen, Hongzhou Lu |
| 24 |
[GO] |
2021―Jul―14 |
The impact of COVID-19 pandemic on the utilization of ambulatory care for patients with chronic neurological diseases in Japan: Evaluation of an administrative claims database |
Kenichiro Sato, Tatsuo Mano, Yoshiki Niimi, Atsushi Iwata, Tatsushi Toda, Takeshi Iwatsubo |
| 25 |
[GO] |
2021―Jul―12 |
Infectious disease activity during the COVID-19 epidemic in Japan: Lessons learned from prevention and control measures |
Tatsuo Sawakami, Kenji Karako, Peipei Song, Wataru Sugiura, Norihiro Kokudo |
| 26 |
[GO] |
2021―Jun―30 |
Rapid evolution of the COVID-19 pandemic calls for a unified public health response |
Na He |
| 27 |
[GO] |
2021―Jun―25 |
Impact of China's COVID-19 prevention and control efforts on outbreaks of influenza |
Qian Li, Jun Wang, Haiwei Lv, Hongzhou Lu |
| 28 |
[GO] |
2021―Jun―15 |
Opportunities and challenges to the use of neutralizing monoclonal antibody therapies for COVID-19 |
Jie Su, Hongzhou Lu |
| 29 |
[GO] |
2021―Jun―15 |
What is always necessary throughout efforts to prevent and control COVID-19 and other infectious diseases? A physical containment strategy and public mobilization and management |
Mingyu Luo, Jimin Sun, Zhenyu Gong, Zhen Wang |
| 30 |
[GO] |
2021―Mrz―25 |
Rapid SARS-CoV-2 antigen detection potentiates early diagnosis of COVID-19 disease |
Ying Lv, Yuanyuan Ma, Yanhui Si, Xiaoyi Zhu, Lin Zhang, Haiyan Feng, Di Tian, Yixin Liao, Tiefu Liu, Hongzhou Lu, Yun Ling |
| 31 |
[GO] |
2021―Mrz―25 |
Burnout in nurses during the COVID-19 pandemic in China: New challenges for public health |
Lin Zhang, Ling Chai, Yihong Zhao, Lin Wang, Wenxiu Sun, Lingqing Lu, Hongzhou Lu, Jianliang Zhang |
| 32 |
[GO] |
2021―Mrz―18 |
COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer |
Yamin Chen, Luying Cheng, Rongna Lian, Ziwei Song, Jinhui Tian |
| 33 |
[GO] |
2021―Mrz―18 |
New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals |
Jun Chen, Hongzhou Lu |
| 34 |
[GO] |
2021―Feb―22 |
Transitional care during COVID-19 pandemic in Japan: Calls for new strategies to integrate traditional approaches with information and communication technologies |
Yuka Sumikawa, Noriko Yamamoto-Mitani |
| 35 |
[GO] |
2021―Jan―28 |
Overview of the characteristics of and responses to the three waves of COVID-19 in Japan during 2020-2021 |
Kenji Karako, Peipei Song, Yu Chen, Wei Tang, Norihiro Kokudo |
| 36 |
[GO] |
2020―Dez―26 |
Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19? |
Masashi Ohe, Ken Furuya, Houman Goudarzi |
| 37 |
[GO] |
2020―Dez―24 |
Latest updates on COVID-19 vaccines |
Qian Li, Hongzhou Lu |
| 38 |
[GO] |
2020―Dez―17 |
Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China |
Yi Su, Yun Ling, Yuyan Ma, Lili Tao, Qing Miao, Qingfeng Shi, Jue Pan, Hongzhou Lu, Bijie Hu |
| 39 |
[GO] |
2020―Okt―24 |
An overview of potential therapeutic agents to treat COVID-19 |
Xueqin Dong, Zhenxue Tian, Chengwu Shen, Cuirong Zhao |
| 40 |
[GO] |
2020―Okt―24 |
The development of a quarantine strategy is an important path to a normalized response to COVID-19 |
Han Zhu, Hongzhou Lu |
| 41 |
[GO] |
2020―Jun―20 |
Exploration and correlation analysis of changes in Krebs von den Lungen-6 levels in COVID-19 patients with different types in China |
Mingshan Xue, Peiyan Zheng, Xiqing Bian, Zhifeng Huang, Huimin Huang, Yifeng Zeng, Haisheng Hu, Xiaoqing Liu, Luqian Zhou, Baoqing Sun, Jian-lin Wu, Nanshan Zhong |
| 42 |
[GO] |
2020―Jun―11 |
Potential for jaktinib hydrochloride to treat cytokine storms in patients with COVID-19 |
Xianmin Meng, Yun Ling, Li Zhang, Qian Zhang, Ping Dong, Tongyu Zhu, Hongzhou Lu |
| 43 |
[GO] |
2020―Mai―27 |
Predicting intervention effect for COVID-19 in Japan: state space modeling approach |
Genya Kobayashi, Shonosuke Sugasawa, Hiromasa Tamae, Takayuki Ozu |
| 44 |
[GO] |
2020―Mai―15 |
Does immune privilege result in recovered patients testing positive for COVID-19 again? |
Jufeng Xia |
| 45 |
[GO] |
2020―Mai―08 |
Introduction on collective quarantine of close contacts of patients with COVID-19 for medical observation in China: from the perspective of frontline staff |
Chenjie Dong, Yuan Tian, Wenzhong Xu, Jiangjiang He, Duo Chen, Jie Zhu, Ping Lu |
| 46 |
[GO] |
2020―Apr―29 |
Analysis of coagulation parameters in patients with COVID-19 in Shanghai, China |
Ying Zou, Hongying Guo, Yuyi Zhang, Zhengguo Zhang, Yu Liu, Jiefei Wang, Hongzhou Lu, Zhiping Qian |
| 47 |
[GO] |
2020―Apr―26 |
Suggestions on surgical treatment during coronavirus disease 2019 (COVID-19) pandemic |
Zhiming Zhao, Mengyang Li, Rong Liu |
| 48 |
[GO] |
2020―Apr―21 |
Asymptomatic carriers of COVID-19 as a concern for disease prevention and control: more testing, more follow-up |
Jiao Zhang, Shoucai Wu, Lingzhong Xu |
| 49 |
[GO] |
2020―Apr―21 |
A practice of anesthesia scenario design for emergency cesarean section in patients with COVID-19 infection based on the role of standard patient |
Yin Kang, Longjiao Deng, Dengwen Zhang, Yuehong Wang, Gang Wang, Li Mei, Guobin Zhou, Haihua Shu |
| 50 |
[GO] |
2020―Apr―12 |
Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19) |
Jianjun Gao, Shasha Hu |
| 51 |
[GO] |
2020―Apr―04 |
Macrolide treatment for COVID-19: Will this be the way forward? |
Masashi Ohe, Haruki Shida, Satoshi Jodo, Yoshihiro Kusunoki, Masahide Seki, Ken Furuya, Houman Goudarzi |
| 52 |
[GO] |
2020―Mrz―31 |
Mobile field hospitals, an effective way of dealing with COVID-19 in China: sharing our experience |
Zhi Chen, Shan He, Fan Li, Junxiang Yin, Xiaoliang Chen |
| 53 |
[GO] |
2020―Mrz―18 |
Analysis of COVID-19 infection spread in Japan based on stochastic transition model |
Kenji Karako, Peipei Song, Yu Chen, Wei Tang |
| 54 |
[GO] |
2020―Feb―24 |
COVID-19: Real-time dissemination of scientific information to fight a public health emergency of international concern |
Peipei Song, Takashi Karako |
| 55 |
[GO] |
2020―Feb―18 |
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies |
Jianjun Gao, Zhenxue Tian, Xu Yang |
| 56 |
[GO] |
2020―Feb―16 |
Challenges to the system of reserve medical supplies for public health emergencies: reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China |
Xu Wang, Xiaoxi Zhang, Jiangjiang He |
| 57 |
[GO] |
2020―Feb―08 |
Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment |
Zhenwei Wang, Xiaorong Chen, Yunfei Lu, Feifei Chen, Wei Zhang |
| 58 |
[GO] |
2020―Jan―27 |
Drug treatment options for the 2019-new coronavirus (2019-nCoV) |
Hongzhou Lu |
